BTN3A1 and neoplasm: Our data establish Vγ9Vδ2 T cell as a potent anti‐CC immune cell that can synergize with αβ T cell through direct tumor‐killing, antigen presentation and relieving BTN3A1‐mediated αβ T cell inhibition.